|Bid||0.00 x 3000|
|Ask||0.00 x 1300|
|Day's Range||3.47 - 3.66|
|52 Week Range||1.59 - 5.83|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 6, 2018 - Aug 10, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||7.00|
Positive seasonality for small caps and penny stocks has ended. Legacy Reserves LP ( LGCY) soared nearly 84% in the first two weeks of the month, posting a 3-year high, while solar manufacturer Enphase Energy, Inc. ( ENPH) broke out of a 2-month basing pattern and gained 40%. Enphase Energy, Inc. ( ENPH) posted an-all time high at $17.97 in September 2014 and broke down in May 2015, entering a brutal decline that ended at an all-time low at 65-cents in the second quarter of 2017.
Revenue increased 203% compared to the three-month period in the prior year. Call scheduled for today, May 10, at 4:30 pm ET. TUCSON, Ariz., May 10, 2018-- HTG Molecular Diagnostics, Inc., a provider of ...
Examining HTG Molecular Diagnostics Inc’s (NASDAQ:HTGM) past track record of performance is an insightful exercise for investors. It allows us to reflect on whether or not the company has metRead More...
HTG Molecular Diagnostics, Inc. (HTGM) (HTG), a provider of instruments, reagents, and services for molecular profiling applications, today announced that it will feature its HTG EdgeSeq Precision Immuno-Oncology Panel at the American Society of Clinical Oncology (ASCO) Conference being held in Chicago, IL on June 1-5, 2018. “We are very excited to introduce our new HTG EdgeSeq Precision Immuno-Oncology Panel at the 2018 ASCO conference. As Immuno-Oncology matures as a field, it is critical that translational tools evolve with the science to address immunotherapy acquired resistance or lack of response seen in broader cancer patient populations,” said Mark Stern, Vice President of Immuno-Oncology at HTG. “We have designed this panel to facilitate the molecular subtyping of tumors, allowing for the potential stratification of cancer into biological sub-groups, which might be sensitive to newly developed combination treatments.
HTG Molecular Diagnostics, Inc. (HTGM) (“HTG”), a provider of instruments, reagents and services for molecular profiling applications, and Firalis S.A. (“Firalis”), a provider of bioanalytical services and biomarker-based products and services, today announced a non‑exclusive license and supply agreement (“Agreement”) that will enable Firalis to commercialize a next‑generation sequencing (NGS)‑based theranostic product and services to predict rheumatoid arthritis (RA) patients response to anti‑TNFα therapy, and other research products and services for mRNA profiling of inflammatory‑autoimmune disorders. The Agreement is a next step in the parties’ relationship following the successful adaptation of Firalis’ BIOPRED* research‑use assay to HTG EdgeSeq technology.
NEW YORK, May 02, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of HTG ...
The Russell-2000 small-cap index held up better than the S&P 500 or Nasdaq-100, with trade tensions favoring small domestic issues over multinational giants. Low-priced sector plays have gained ground as well, with a broad basket of penny stocks posting 52-week highs. Legacy Reserves LP ( LGCY) posted the most substantial returns on April’s penny stocks watch list, gaining nearly 18% in sympathy with energy sector buying interest.
TUCSON, Ariz., April 27, 2018-- HTG Molecular Diagnostics, Inc., a provider of instruments, reagents, and services for molecular profiling applications, today announced that it will report its financial ...
Lubniewski assumes the role after having served for seven years as Chief Business Officer. TUCSON, Ariz., April 16, 2018-- HTG Molecular Diagnostics, Inc., a provider of instruments, reagents, and services ...
Patent covers nuclease protection methods for detection of nucleotide variants. TUCSON, Ariz., April 03, 2018-- HTG Molecular Diagnostics, Inc., a provider of instruments, reagents, and services for molecular ...
TUCSON, Ariz., March 27, 2018-- HTG Molecular Diagnostics, Inc., a provider of instruments, reagents and services for molecular profiling applications today announced that it has entered into a senior ...
The Dow Jones Industrial Average dropped more than 700 points on a down day for U.S. equities in which President Donald Trump announced tariffs on international imports from China. The index fell 2.9% Thursday, while the S&P 500 Index fell 2.5% and the Nasdaq Composite fell 2.4%.
Revenue increased 442% and 188%, respectively, compared to the three and twelve month periods in the prior year driven by development efforts supporting Pharma clinical programs. TUCSON, Ariz., March 22, ...
NEW YORK, NY / ACCESSWIRE / March 22, 2018 / HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM ) will be discussing their earnings results in their Q4 Earnings Call to be held on March 22, 2018, at 4:30 PM ...